Novartis announced that the Phase III REACH3 study evaluating Jakavi® (ruxolitinib) in patients with steroid-refractory or steroid-dependent chronic graft-versus-host disease (GvHD) met its primary endpoint of superior overall response rate (ORR) at Week 24 versus best available therapy (BAT).
Jnana Therapeutics has signed a multi-target collaboration and license deal worth over $1bn with Roche for the discovery of small molecule drugs for the treatment of immune-mediated and neurological diseases.
Gilead Sciences has agreed to invest up to $300m to acquire a 49.9% equity stake in clinical-stage immunotherapy company Tizona Therapeutics.
JW Therapeutics announced the acquisition of Syracuse Biopharma (Hong Kong) Limited, which includes the license for Eureka Therapeutics’ ARTEMIS antibody TCR and solid tumor technology for exclusive use in China and the ASEAN countries.
British drugmaker GlaxoSmithKline (GSK) has agreed to invest up to €150m to acquire a 10% stake in German biotech company CureVac.
Tonix Pharmaceuticals Holding, a clinical-stage biopharmaceutical company, announced it has entered into a research collaboration and option agreement with Columbia University focused on studying the immune responses to COVID-19 in healthy volunteers who have recovered from COVID-19 or were asymptomatic.
A common drug, already approved by the Food and Drug Administration (FDA), may also be a powerful tool in fighting COVID-19, according to research published this week in Antiviral Research.
Roche and Blueprint Medicines have signed a global licensing and collaboration deal worth up to $1.7bn for the latter's pralsetinib, an investigational treatment for RET-altered cancers.
Merck, a leading science and technology company, opened its M Lab Collaboration Centre in Shanghai, the company's largest of nine centers worldwide.
Kymera Therapeutics announced the company has entered into a multi-program strategic collaboration with Sanofi to develop and commercialise first-in-class protein degrader therapies targeting IRAK4 in patients with immune-inflammatory diseases.
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.